Table 1.
Clinical and pathologic characteristics of the patients
| Characteristic | Number | % |
|---|---|---|
| Number of patients | 28 | 100.0 |
| Age (years) | ||
| <50 | 18 | 64.3 |
| ≥50 | 10 | 35.7 |
| Clinical (T) stage | ||
| T2 | 15 | 53.6 |
| T3 | 6 | 21.4 |
| T4d | 7 | 25.0 |
| LVSI | ||
| Negative | 12 | 42.9 |
| Positive | 16 | 27.1 |
| Type of lesion | ||
| Unifocal | 9 | 32.1 |
| Multifocal | 10 | 45.8 |
| Multifocal and multicentric | 9 | 32.1 |
| Grade | ||
| 1 | 5 | 17.9 |
| 2 | 9 | 32.1 |
| 3 | 14 | 50.0 |
| Tumor size before CTX | ||
| 20–30 mm | 13 | 46.4 |
| 31–50 mm | 4 | 14.4 |
| >50 mm | 11 | 39.2 |
| Pathological (ypT) stage | ||
| ypT0 | 2 | 7.1 |
| ypT1 | 10 | 35.7 |
| ypT2 | 11 | 39.3 |
| ypT3 | 1 | 3.6 |
| ypT4 | 4 | 14.3 |
| Tumor histology | ||
| Ductal | 12 | 42.9 |
| Lobular | 10 | 35.7 |
| Mixed | 3 | 10.7 |
| Other | 3 | 10.7 |
| ER status | ||
| Negative | 7 | 25.0 |
| Positive | 21 | 75.0 |
| PgR status | ||
| Negative | 8 | 28.6 |
| Positive | 20 | 71.4 |
| HER2 status | ||
| Negative | 23 | 82.1 |
| Positive | 5 | 17.9 |
| Ki-67 | ||
| <15% | 11 | 39.3 |
| ≥15% | 17 | 60.7 |
| <50% | 21 | 75.0 |
| ≥50% | 7 | 25.0 |
Abbreviations: CTX, chemotherapy; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LVSI, lymphovascular space invasion; PgR, progesterone receptor.